Vaxart COVID-19 vaccine
Vaxart COVID-19 vaccine is a COVID-19 vaccine candidate developed by Vaxart.[1][2][3]
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Viral vector |
Clinical data | |
Other names | VXA-CoV2-1, VXA-CoV2-1.1-S |
Routes of administration | Oral |
References
- Clinical trial number NCT04563702 for "Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults" at ClinicalTrials.gov
- Clinical trial number NCT05067933 for "Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine (VXA-NVV-104)" at ClinicalTrials.gov
- Clinical trial number NCT05067933 for "A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine" at ClinicalTrials.gov
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.